CNV2197944: Phase II started

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled, crossover, Hungarian Phase II trial to evaluate 75 mg oral CNV2197944 thrice daily for 3 weeks in about 16...